With regard to CATMAT, I would clarify that the CATMAT recommendations are intended for clinicians, not for the general public. It's not meant as a source of advice for the general public. It's meant to guide clinicians who are themselves advising travellers.
The warnings that came onto mefloquine are there because there have been cases that have been reported, not because it has been definitively shown that those cases were due to mefloquine but that it is a potential risk. That's there for the reason that it's a potential risk to be taken into account when advising anybody. It does seem to be very rare.
In our practice with travellers, as opposed to the military, we do this on a case-to-case basis. We talk to people. There are some advantages, for example, to mefloquine. One of the biggest problems we have, as I mentioned very briefly at the beginning, is that people don't take the medication. They are prescribed something, they don't take it, and then they get malaria and they get sick.